Wal-Mart pharmacy programs has industry rethinking benefit approaches.
Wal-Mart is offering a series of programs to administer exclusive pharmacy benefits for employers.
The retailer is offering businesses low-priced drugs if they sign up to buy directly from Wal-Mart’s network of in-store pharmacies, rather than contracting to buy drugs through PBMs.
“Their approach is representative of a fundamental shift away from, and independence from, the traditional pharmacy benefit management model,” says Robert Taketomo, PharmD, MBA, president and CEO of Ventegra in Glendale, Calif. “As more companies seeking innovative and transparent solutions adopt this approach, the existing PBM infrastructure may be replaced.”
Medco spokesperson Jennifer Leone Luddy, disagrees. “This is geographically concentrated pilot-program that seems to be more of a pricing tactic than a game-changing business move,” Luddy says. “And just as their $4 generic program helped boost awareness and acceptance of the use of generic medications, we think this program adds validation to the advantages of using a mail-order pharmacy for chronic medications.”
Luddy advises managed care executives to look beyond unit price of a single drug product and consider the total value of a mail-order pharmacy benefit program, which can offer “the same-or better-generic pricing, more generic products, ensure consistency in the out-of-pocket costs for the consumer, and most importantly, offer enhanced, personalized clinical care.”
Brand drug costs, on average, comprise 85% of a Medco client’s spend, according to Luddy. “Therefore, managing just generics without brand considerations, and without a pharmacy with the scale to negotiate the best prices, places a client and their members at a significant disadvantage.”
Clinic Capture
In other Wal-Mart news, the retailer is rebuilding its walk-in medical clinic business, this time mostly in partnership with hospitals. At the end of 2008, Wal-Mart closed all but 17 of its 78 clinics.
The move by Wal-Mart comes as CVS is also elevating its in-store clinics, and reflects the big retailer’s desire to capture yet another chunk of the consumer’s spending budget, according to Joseph Paduda, principal, Health Strategy Associates LLC.
“The relationship with hospitals is a smart one; hospitals have the clinical, credentialing, and staff resources; Wal-Mart has the customers that hospitals want to turn into patients,” Paduda says. “There is minimal financial risk for Wal-Mart, and nothing but upside for hospitals.”
The re-entry of Wal-Mart into the retail clinic business is likely driven by several factors. “The company, and its hospital partners, recognize that some form of national healthcare reform is possible,” Paduda explains. “If that happens, many Wal-Mart customers who are currently uninsured will have coverage, and their care will be reimbursed-good news for hospitals and Wal-Mart alike.”
It is also possible that Wal-Mart is considering entering the direct contract business, wherein it would become the provider and “insurer” in a vertically integrated health plan model.
“This isn't as far-fetched as it sounds,” Paduda says. “By partnering with full-service hospitals, and with Wal-Mart’s expertise in supply chain management, data mining knowledge and strong brand, the company could become a major ‘health plan’ in its own right.”
David Calabrese of OptumRx Talks New Role, Market Insulin Prices and Other Topics 'On His Mind'
April 13th 2023In this month’s episode of the "What's On Your Mind podcast," Peter Wehrwein, managing editor of MHE connects with the now Chief Clinical Officer of OptumRx Integrated Pharmacies, David Calabrese. In this conversation, David touches on his transition in January as OptumRx’s former chief pharmacy officer and market president of health plans and PBMs to his new role as Chief Clinical Officer where he now focuses more on things such as specialty pharmacy to home delivery — with an overall goal of creating whole-patient care. Throughout the conversation, Calabrese also touched on the market’s hot topic of insulin prices and behavioral health services within the OptumRx community, among other topics.
Listen
Briana Contreras, editor of Managed Healthcare Executive, spoke with Nancy Lurker, CEO and president of EyePoint Pharmaceuticals. Nancy shared a bit about EyePoint and how the organization’s innovative therapies are addressing patient needs through eye care, and most importantly, she addressed C-Suite positions like the CEO role. Nancy shared advice for those seeking to reach the CEO level, especially toward women in healthcare and other roles, and what it takes to run a biopharma company.
Listen
Upended: Can PBM Transparency Succeed?
March 6th 2024Simmering tensions in the pharmacy benefit management (PBM) industry have turned into fault lines. The PBMs challenging the "big three" have formed a trade association. Purchaser coalitions want change. The head of the industry's trade group says inherent marketplace friction has spilled over into political friction.
Read More
Florida Gets the OK. But Will Drug Importation from Canada Actually Happen?
March 5th 2024Canadian health officials warn that maintaining a drug supply for Canadians is their priority. The staunch opposition of the U.S. pharmaceutical industry may also be an obstacle to imports from north of the border.
Read More